Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb 5;14(2):e0211830.
doi: 10.1371/journal.pone.0211830. eCollection 2019.

The Apparent Diffusion Coefficient (ADC) is a useful biomarker in predicting metastatic colon cancer using the ADC-value of the primary tumor

Affiliations

The Apparent Diffusion Coefficient (ADC) is a useful biomarker in predicting metastatic colon cancer using the ADC-value of the primary tumor

Elias Nerad et al. PLoS One. .

Abstract

Purpose: To investigate the role of the apparent diffusion coefficient (ADC) as a potential imaging biomarker to predict metastasis (lymph node metastasis and distant metastasis) in colon cancer based on the ADC-value of the primary tumor.

Methods: Thirty patients (21M, 9F) were included retrospectively. All patients received a 1.5T MRI of the colon including T2 and DWI sequences. ADC maps were calculated for each patient. An expert reader manually delineated all colon tumors to measure mean ADC and histogram metrics (mean, min, max, median, standard deviation (SD), skewness, kurtosis, 5th-95th percentiles) were calculated. Advanced colon cancer was defined as lymph node mestastasis (N+) or distant metastasis (M+). The student Mann Whitney U-test was used to assess the differences between the ADC means of early and advanced colon cancer. To compare the accuracy of lymph node metastasis (N+) prediction based on morpholigical criteria versus ADC-value of the primary tumor, two blinded readers, determined the lymph node metastasis (N0 vs N+) based on morphological criteria. The sensitivity and specificity in predicting lymph node metastasis was calculated for both readers and for the ADC-value of the primary tumor, with histopathology results as the gold standard.

Results: There was a significant difference between the mean ADC-value of advanced versus early tumors (p = 0.002). The optimal cut off value was 1179 * 10-3 mm2/s with an area under the curve (AUC) of 0.83 and a sensitivity and specificity of 81% and 86% respectively to predict advanced tumors. Histogram analyses did not add any significant additional value. The sensitivity and specificity for the prediction of lymph node metastasis based on morphological criteria were 40% and 63% for reader 1 and 30% and 88% for reader 2 respectively. The primary tumor ADC-value using 1.179 * 10-3 mm2/s as threshold had a 100% sensitivity and specificity in predicting lymph node metastasis.

Conclusion: The ADC-value of the primary tumor has the potential to predict advanced colon cancer, defined as lymph node metastasis or distant metastasis, with lower ADC values significantly associated with advanced tumors. Furthermore the ADC-value of the primary tumor increases the prediction accuracy of lymph node metastasis compared with morphological criteria.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Boxplots for the mean ADC value for early and advanced tumors.
ADC values given in mm2/s x 10−3. ADC = apparent diffusion coefficient.
Fig 2
Fig 2. ROC curve for optimal cut of value.
Optimal cut off value receiver operating characteristic (ROC) curve of the mean ADC with an area under the curve (AUC) of 0.83.
Fig 3
Fig 3. Example of image processing.
The T2 weighted MRI sequence (top picture) is showing the tumor in the sigmoid colon (arrow). The middle picture is the corresponding b1000 weighted DWI (Diffusion Weighted Imaging) sequence showing a high signal intensity within the tumor (consistent with malignancy). Bottom picture shows an example of tumor delineation on the corresponding ADC (Apparent Diffusion Coefficient) as performed to obtain the mean ADC-value of the whole tumor. An abdominal radiologist with 13 years experience in reading abdominal MRI and a radiology resident delineated each tumor in consensus directly on the ADC map whilst referring to the T2 weighted images (top) and the DWI sequence (middle) for anatomical reference.

References

    1. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, et al. (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351: 1731–1740. 10.1056/NEJMoa040694 - DOI - PubMed
    1. Trojan J, Lubomierski N, Lehnert T, Engels K, Zeuzem S, et al. (2008) Neoadjuvant treatment with cetuximab, 5-Fluorouracil, folinic Acid and oxaliplatin in unresectable retroperitoneal recurrent colon cancer. Z Gastroenterol 46: 776–779. 10.1055/s-2007-963717 - DOI - PubMed
    1. Ojima E, Nakano T, Kanamoto A, Sasaki S (2013) [A case of advanced colon cancer successfully treated with combination therapy of cetuximab and oxaliplatin, leucovorin, and 5-fluorouracil]. Gan To Kagaku Ryoho 40: 1962–1964. - PubMed
    1. Arredondo J, Martinez P, Baixauli J, Pastor C, Rodriguez J, et al. (2014) Analysis of surgical complications of primary tumor resection after neoadjuvant treatment in stage IV colon cancer. J Gastrointest Oncol 5: 148–153. 10.3978/j.issn.2078-6891.2014.015 - DOI - PMC - PubMed
    1. Dam C, Lund-Rasmussen V, Ploen J, Jakobsen A, Rafaelsen SR (2015) Computed tomography assessment of early response to neoadjuvant therapy in colon cancer. Dan Med J 62. - PubMed

Substances